Intech Investment Management LLC Acquires Shares of 41,047 Cerus Co. (NASDAQ:CERS)

Intech Investment Management LLC purchased a new stake in Cerus Co. (NASDAQ:CERS) in the third quarter, Holdings Channel reports. The firm purchased 41,047 shares of the biotechnology company’s stock, valued at approximately $71,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CERS. Vanguard Group Inc. raised its stake in Cerus by 1.1% during the first quarter. Vanguard Group Inc. now owns 9,983,963 shares of the biotechnology company’s stock worth $18,870,000 after purchasing an additional 113,292 shares during the period. Hood River Capital Management LLC raised its position in Cerus by 390.4% in the second quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock valued at $2,587,000 after purchasing an additional 1,170,060 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Cerus by 6.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,257,571 shares of the biotechnology company’s stock valued at $2,188,000 after buying an additional 71,007 shares during the period. Bank of New York Mellon Corp boosted its holdings in Cerus by 10.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 614,446 shares of the biotechnology company’s stock valued at $1,081,000 after acquiring an additional 57,073 shares during the period. Finally, Bouvel Investment Partners LLC increased its stake in Cerus by 87.1% during the third quarter. Bouvel Investment Partners LLC now owns 505,020 shares of the biotechnology company’s stock worth $879,000 after purchasing an additional 235,082 shares during the period. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus reduced their price target on Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Cerus Stock Performance

NASDAQ:CERS opened at $1.78 on Monday. The business’s fifty day moving average price is $1.74 and its 200 day moving average price is $1.91. The firm has a market capitalization of $330.56 million, a PE ratio of -16.18 and a beta of 1.24. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.59. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.